77.4 F
New York
Thursday, July 29, 2021

Pfizer-BioNTech Plans to Expand Conditional Marketing Authorization of COMIRNATY

Must read

Digital Realty [NYSE: DLR] Considering Developing 64 MW Facility in South Korea

Digital Realty Trust, Inc. has shown its intention to build the 64-megawatt facility in Seoul, South Korea. The firm has decided that the...

Why Shares of IZEA Worldwide [NASDAQ: IZEA] Skyrocketing Today?

Shares of IZEA Worldwide, Inc. surged 8.10% at the time of writing on Wednesday. The strong performance of the firm has highlighted the...

BIT Mining [NYSE: BTCM] Ink Purchase Agreement to Buy Bitcoin Mining Machine

BIT Mining Limited has inked a purchase agreement to increase the fleet of bitcoin mining machines. As per the new purchase agreement, the...

Dyadic International [NASDAQ: DYAI] Inks Licensing Agreement with the Rubic Consortium

Dyadic International, Inc. disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been...

Pfizer Inc. [NYSE: PFE] and BioNTech SE [NASDAQ: BNTX] disclosed that it has decided to submit a change to the Conditional Marketing Authorization (CMA) in the EU to the EMA for the Pfizer-BioNTech vaccine COMIRNATY (BNT162b2) to ask for a delay of the suggestion for use in adolescents 12 to 15 years of age.

It has been disclosed that if the modified version of CMA will be authorized by EMA then it will be valid in all the 27 member states of the EU. Furthermore, the firms have already filed a related application to the U.S. FDA for the EUA. Moreover, it is planning to ask for further changes with other regulatory agencies around the world.

Additionally, it has been uncovered by the firms that their submission is dependent on the pivotal Phase III clinical study. The Phase III study has registered 2,260 applicants aged 12 to 15 years. Earlier on March 31, 2021, the firms have revealed the results of the study. The outcome of the study indicated the 100% potency in volunteers with or without before SARS-CoV-2 infection and vigorous antibody responses.

Furthermore, the volunteers have also easily tolerated the vaccine. The firm has decided to monitor the volunteers for safety for an extra two years after their second dose. The Pfizer-BioNTech’s vaccine is based on BioNTech patented mRNA technology. It was established by both BioNTech and Pfizer. Moreover, BioNTech is the possessor of MA in the EU. It also holds emergency use authorizations or equivalent in the UK, Canada, and the US.

More articles

Latest article

Binance, FTX Cut Leverage Limits on Crypto Futures Trading to 20x

Two major cryptocurrency trading platforms Binance Futures and FTX disclosed on Monday that they both have made a remarkable decision related to the crypto...

TD Holdings [NASDAQ: GLG] Inks Letter of Intent with Guangdong Jinbochuang

TD Holdings, Inc. has inked a letter of intent (LOI) with Guangdong Jinbochuang Special Purpose Vehicle Co., Ltd. and (Jinbochuang) and Hunan Jinmeike...

ASGN [NYSE: ASGN] Acquire IndraSoft Inc

ASGN Incorporated disclosed that it has acquired IndraSoft Inc. IndraSoft Inc has gained recognition as a prominent cybersecurity and digital transformation solutions offeror...

Link Reservations Decides to Accept Bitcoin/Crypto Payments

Link Reservations Inc disclosed Friday that it has decided to start accepting Bitcoin and cryptocurrency payments. This is the major breakthrough for the firm...

Athene [NYSE: ATH] Announces Acquisition of Foundation Home Loans

Athene Holding Ltd. disclosed on Thursday that it has inked a definitive agreement to purchase Foundation Home Loans (FHL). FHL had a £3...

Ping [NYSE: PING] and Anexinet Announces Partnership

Ping Identity Holding Corp. and Anexinet Corporation have both entered into a partnership agreement. The collaboration will integrate Ping Identity’s centralized Identity Access...

Digital Realty [NYSE: DLR] and Brookfield Announces Joint Venture

Digital Realty Trust, Inc.   and Brookfield Infrastructure Partners L.P. and its institutional partners disclosed on Wednesday that they have launched a 50/50 joint...

Red Cat [NASDAQ: RCAT] Announces Acquisition of Teal Drones

Red Cat Holdings, Inc. has inked an agreement on Tuesday to buy Teal Drones in an all-stock transaction. This acquisition will add Teal...